Advancis Pharmaceutical Changes Its Name to MiddleBrook Pharmaceuticals, Inc.
28 Junio 2007 - 7:00AM
PR Newswire (US)
GERMANTOWN, Md., June 28 /PRNewswire-FirstCall/ -- Advancis
Pharmaceutical Corporation (NASDAQ:AVNC), a pharmaceutical company
focused on developing and commercializing novel anti-infective
products, today announced that the Company has changed its name to
MiddleBrook Pharmaceuticals, Inc. The name change, effective
immediately, was completed pursuant to the Company's jointly
submitted Permanent Injunction and Order with sanofi-aventis of
October 27, 2006, whereby the Company agreed to cease using the
Advancis name by June 30, 2007. In conjunction with the new name,
the Company will change its NASDAQ trading symbol to MBRK,
effective with the start of trading on June 29, 2007. "All elements
of the Company's business and future strategy remain unchanged,"
said Dr. Edward Rudnic, MiddleBrook president and CEO. "As we move
forward under the new MiddleBrook name, we expect to continue to
execute upon our previously laid-out plan of supporting our
Amoxicillin PULSYS regulatory filing currently under FDA review,
marketing our branded Keflex antibiotic franchise, and positioning
our other PULSYS product candidates for further development." In
addition, the Company is continuing its previously announced
process to explore strategic alternatives and that process is
ongoing. About Middlebrook Pharmaceuticals: MiddleBrook
Pharmaceuticals, Inc. (NASDAQ:MBRKNASDAQ:formerlyNASDAQ:Advancis
PharmaceuticalNASDAQ:CorporationNASDAQ:Nasdaq:NASDAQ:AVNC) is a
pharmaceutical company focused on the development and
commercialization of anti-infective drug products that fulfill
substantial unmet medical needs in the treatment of infectious
disease. The Company is developing a portfolio of anti-infective
drugs based on its novel biological finding that bacteria exposed
to antibiotics in front- loaded staccato bursts, or "pulses," are
killed more efficiently and effectively than those under standard
treatment regimens. Based on this finding, MiddleBrook has
developed a proprietary, once-a-day pulsatile delivery technology
called PULSYSTM. By examining the resistance patterns of bacteria
and applying its delivery technologies, MiddleBrook has the
potential to redefine infectious disease therapy and significantly
improve drug efficacy, shorten length of therapy, and reduce drug
resistance versus currently available antibacterial products. For
more on MiddleBrook, please visit
http://www.middlebrookpharma.com/. This announcement contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These statements are
based on MiddleBrook's current expectations and assumptions. These
statements are not guarantees of future performance and are subject
to a number of risks and uncertainties that would cause actual
results to differ materially from those anticipated. The words,
"believe," "expect," "intend," "anticipate," and variations of such
words, and similar expressions identify forward-looking statements,
but their absence does not mean that the statement is not forward-
looking. Statements in this announcement that are forward-looking
include, but are not limited to, statements about the Company's
future development plans, clinical trials, potential commercial
success, and any financial forecasts included in this announcement.
The actual results realized by MiddleBrook could differ materially
from these forward-looking statements, depending in particular upon
the risks and uncertainties described in the Company's filings with
the Securities and Exchange Commission. These include, without
limitation, risks and uncertainties relating to the Company's
financial results and the ability of the Company to (1) raise
additional capital and continue as a going concern, (2) increase
Keflex 750 sales, (3) obtain FDA approval for its Amoxicillin
PULSYS product candidate, (4) successfully reduce costs, (5)
maintain compliance with its outstanding credit facility with
Merrill Lynch Capital, (6) reach profitability, (7) prove that the
preliminary findings for its product candidates are valid, (8)
receive required regulatory approvals, (9) successfully conduct
clinical trials in a timely manner, (10) establish its competitive
position for its products, (11) develop and commercialize products
that are superior to existing or newly developed competitor
products, (12) develop products without any defects, (13) have
sufficient capital resources to fund its operations, (14) protect
its intellectual property rights and patents, (15) implement its
sales and marketing strategy, (16) successfully attract and retain
collaborative partners, (17) successfully commercialize and gain
market acceptance for its Keflex products, (18) successfully obtain
sufficient manufactured quantities of its drug products at
acceptable rates, and (19) retain its senior management and other
personnel. Existing and prospective investors are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of today's date. MiddleBrook undertakes no obligation
to update or revise the information in this announcement, whether
as a result of new information, future events or circumstances or
otherwise. DATASOURCE: MiddleBrook Pharmaceuticals, Inc. CONTACT:
Robert Bannon, Vice President, Investor Relations & Corporate
Communications, of MiddleBrook Pharmaceuticals, Inc., ,
+1-301-944-6710 Web site: http://www.advancispharm.com/
http://www.middlebrookpharma.com/
Copyright
Advancis (NASDAQ:AVNC)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Advancis (NASDAQ:AVNC)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024